Abstract
The use of cells derived from pluripotent stem cells (PSCs) for regenerative therapies confers a considerable risk for neoplastic growth and teratoma formation. Preclinical and clinical assessment of such therapies will require suitable monitoring strategies to understand and mitigate these risks. Here we generated human-induced pluripotent stem cells (iPSCs), selected clones that continued to express reprogramming factors after differentiation into cardiomyocytes, and transplanted these cardiomyocytes into immunocompromised rat hearts post-myocardial infarction. We compared magnetic resonance imaging (MRI), cardiac ultrasound, and serum biomarkers for their ability to delineate teratoma formation and growth. MRI enabled the detection of teratomas with a volume >8 mm3. A combination of three plasma biomarkers (CEA, AFP, and HCG) was able to detect teratomas with a volume >17 mm3 and with a sensitivity of more than 87%. Based on our findings, a combination of serum biomarkers with MRI screening may offer the highest sensitivity for teratoma detection and tracking.
Original language | English (US) |
---|---|
Pages (from-to) | 176-187 |
Number of pages | 12 |
Journal | Stem Cell Reports |
Volume | 6 |
Issue number | 2 |
DOIs | |
State | Published - Feb 9 2016 |
Externally published | Yes |
Keywords
- magnetic resonance imaging
- microRNA biomarker
- pluripotent stem cells
- serum biomarker
- tumorigenicity
- ultrasound imaging
ASJC Scopus subject areas
- Biochemistry
- Genetics
- Developmental Biology
- Cell Biology